Anti-Syntrophin antibody [1351]
| Name | Anti-Syntrophin antibody [1351] |
|---|---|
| Supplier | Abcam |
| Catalog | ab11425 |
| Prices | $394.00 |
| Sizes | 50 µg |
| Host | Mouse |
| Clonality | Monoclonal |
| Isotype | IgG1 |
| Clone | 1351 |
| Applications | ICC/IF ICC/IF IP WB IHC-F ICC/IF FC |
| Species Reactivities | Mouse, Rat, Chicken, Dog, Human, Xenopus, Amphibians, Xenopus, Fish |
| Antigen | Other Immunogen Type corresponding to Syntrophin |
| Description | Mouse Monoclonal |
| Gene | SNTA1 |
| Conjugate | Unconjugated |
| Supplier Page | Shop |
Product images
Immunocytochemistry/Immunofluorescence analysis of HeLa cells labeling Syntrophin (green) with ab11425 at 1/20. F-Actin staining with Phalloidin (red) and nuclei with DAPI (blue). Cells were fixed with formaldehyde and incubated with the primary antibody overnight at 4°C. A DyLight 488-conjugated secondary antibody was used. 60X magnification. Right - negative control.
Immunocytochemistry/Immunofluorescence analysis of A2058 cells labeling Syntrophin (green) with ab11425 at 1/20. F-Actin staining with Phalloidin (red) and nuclei with DAPI (blue). Cells were fixed with formaldehyde and incubated with the primary antibody overnight at 4°C. A DyLight 488-conjugated secondary antibody was used. 60X magnification. Right - negative control.
Immunocytochemistry/Immunofluorescence analysis of 293 cells labeling Syntrophin (green) with ab11425 at 1/20. F-Actin staining with Phalloidin (red) and nuclei with DAPI (blue). Cells were fixed with formaldehyde and incubated with the primary antibody overnight at 4°C. A DyLight 488-conjugated secondary antibody was used. 60X magnification. Right - negative control.
![Overlay histogram showing SH-SY5Y cells stained with ab11425 (red line). The cells were fixed with 4% paraformaldehyde (10 min) and then permeabilized with 0.1% PBS-Tween for 20 min. The cells were then incubated in 1x PBS / 10% normal goat serum / 0.3M glycine to block non-specific protein-protein interactions followed by the antibody (ab11425, 0.5µg/1x106 cells) for 30 min at 22ºC. The secondary antibody used was DyLight® 488 goat anti-mouse IgG (H+L) (ab96879) at 1/500 dilution for 30 min at 22ºC. Isotype control antibody (black line) was mouse IgG1 [ICIGG1] (ab91353, 2µg/1x106 cells) used under the same conditions. Acquisition of >5,000 events was performed. This antibody gave a positive signal in SH-SY5Y cells fixed with 80% methanol (5 min)/permeabilized in 0.1% PBS-Tween used under the same conditions.](http://www.bioprodhub.com/system/product_images/ab_products/2/sub_5/7823_Syntrophin-Primary-antibodies-ab11425-1.jpg)
Overlay histogram showing SH-SY5Y cells stained with ab11425 (red line). The cells were fixed with 4% paraformaldehyde (10 min) and then permeabilized with 0.1% PBS-Tween for 20 min. The cells were then incubated in 1x PBS / 10% normal goat serum / 0.3M glycine to block non-specific protein-protein interactions followed by the antibody (ab11425, 0.5µg/1x106 cells) for 30 min at 22ºC. The secondary antibody used was DyLight® 488 goat anti-mouse IgG (H+L) (ab96879) at 1/500 dilution for 30 min at 22ºC. Isotype control antibody (black line) was mouse IgG1 [ICIGG1] (ab91353, 2µg/1x106 cells) used under the same conditions. Acquisition of >5,000 events was performed. This antibody gave a positive signal in SH-SY5Y cells fixed with 80% methanol (5 min)/permeabilized in 0.1% PBS-Tween used under the same conditions.
![All lanes : Anti-Syntrophin antibody [1351] (ab11425) at 5 µg/mlLane 1 : Skeletal Muscle (Human) Tissue Lysate - adult normal tissue (ab29330)Lane 2 : Skeletal Muscle (Rat) Tissue Lysate Lane 3 : Skeletal Muscle (Mouse) Tissue Lysate Lysates/proteins at 20 µg per lane.SecondaryGoat polyclonal Secondary Antibody to Mouse IgG - H&L (HRP), pre-adsorbed at 1/5000 dilutiondeveloped using the ECL techniquePerformed under reducing conditions.](http://www.bioprodhub.com/system/product_images/ab_products/2/sub_5/7824_Syntrophin-Primary-antibodies-ab11425-3.jpg)
All lanes : Anti-Syntrophin antibody [1351] (ab11425) at 5 µg/mlLane 1 : Skeletal Muscle (Human) Tissue Lysate - adult normal tissue (ab29330)Lane 2 : Skeletal Muscle (Rat) Tissue Lysate Lane 3 : Skeletal Muscle (Mouse) Tissue Lysate Lysates/proteins at 20 µg per lane.SecondaryGoat polyclonal Secondary Antibody to Mouse IgG - H&L (HRP), pre-adsorbed at 1/5000 dilutiondeveloped using the ECL techniquePerformed under reducing conditions.
Syntrophin was immunoprecipitated using 0.5mg Mouse Skeletal Muscle tissue lysate, 5µg of Mouse monoclonal to Syntrophin and 50µl of protein G magnetic beads (+). No antibody was added to the control (-). The antibody was incubated under agitation with Protein G beads for 10min, Mouse Skeletal Muscle tissue lysate lysate diluted in RIPA buffer was added to each sample and incubated for a further 10min under agitation.Proteins were eluted by addition of 40µl SDS loading buffer and incubated for 10min at 70oC; 10µl of each sample was separated on a SDS PAGE gel, transferred to a nitrocellulose membrane, blocked with 5% BSA and probed with ab11425.Secondary: Goat polyclonal to mouse IgG light chain specific (HRP) at 1/5000 dilution.Band: 58kDa; Syntrophin
Product References
Annotation of loci from genome-wide association studies using tissue-specific - Annotation of loci from genome-wide association studies using tissue-specific
Lundby A, Rossin EJ, Steffensen AB, Acha MR, Newton-Cheh C, Pfeufer A, Lynch SN, Olesen SP, Brunak S, Ellinor PT, Jukema JW, Trompet S, Ford I, Macfarlane PW, Krijthe BP, Hofman A, Uitterlinden AG, Stricker BH, Nathoe HM, Spiering W, Daly MJ, Asselbergs FW, van der Harst P, Milan DJ, de Bakker PI, Lage K, Olsen JV. Nat Methods. 2014 Aug;11(8):868-74.
Microdystrophin ameliorates muscular dystrophy in the canine model of duchenne - Microdystrophin ameliorates muscular dystrophy in the canine model of duchenne
Shin JH, Pan X, Hakim CH, Yang HT, Yue Y, Zhang K, Terjung RL, Duan D. Mol Ther. 2013 Apr;21(4):750-7.
Identification of FHL1 as a therapeutic target for Duchenne muscular dystrophy. - Identification of FHL1 as a therapeutic target for Duchenne muscular dystrophy.
D'Arcy CE, Feeney SJ, McLean CA, Gehrig SM, Lynch GS, Smith JE, Cowling BS, Mitchell CA, McGrath MJ. Hum Mol Genet. 2014 Feb 1;23(3):618-36.
Variable phenotype of del45-55 Becker patients correlated with nNOSmu - Variable phenotype of del45-55 Becker patients correlated with nNOSmu
Gentil C, Leturcq F, Ben Yaou R, Kaplan JC, Laforet P, Penisson-Besnier I, Espil-Taris C, Voit T, Garcia L, Pietri-Rouxel F. Hum Mol Genet. 2012 Aug 1;21(15):3449-60.
An intronic LINE-1 element insertion in the dystrophin gene aborts dystrophin - An intronic LINE-1 element insertion in the dystrophin gene aborts dystrophin
Smith BF, Yue Y, Woods PR, Kornegay JN, Shin JH, Williams RR, Duan D. Lab Invest. 2011 Feb;91(2):216-31.
Sarcolemmal nNOS anchoring reveals a qualitative difference between dystrophin - Sarcolemmal nNOS anchoring reveals a qualitative difference between dystrophin
Li D, Bareja A, Judge L, Yue Y, Lai Y, Fairclough R, Davies KE, Chamberlain JS, Duan D. J Cell Sci. 2010 Jun 15;123(Pt 12):2008-13.
Sub-physiological sarcoglycan expression contributes to compensatory muscle - Sub-physiological sarcoglycan expression contributes to compensatory muscle
Li D, Long C, Yue Y, Duan D. Hum Mol Genet. 2009 Apr 1;18(7):1209-20.
Functional implication of Dp71 in osmoregulation and vascular permeability of the - Functional implication of Dp71 in osmoregulation and vascular permeability of the
Sene A, Tadayoni R, Pannicke T, Wurm A, El Mathari B, Benard R, Roux MJ, Yaffe D, Mornet D, Reichenbach A, Sahel JA, Rendon A. PLoS One. 2009 Oct 7;4(10):e7329.
Prevention of dystrophin-deficient cardiomyopathy in twenty-one-month-old carrier - Prevention of dystrophin-deficient cardiomyopathy in twenty-one-month-old carrier
Bostick B, Yue Y, Long C, Duan D. Circ Res. 2008 Jan 4;102(1):121-30. Epub 2007 Oct 25.
Preservation of muscle force in Mdx3cv mice correlates with low-level expression - Preservation of muscle force in Mdx3cv mice correlates with low-level expression
Li D, Yue Y, Duan D. Am J Pathol. 2008 May;172(5):1332-41.